Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection.
Espeseth AS, Cejas PJ, Citron MP, Wang D, DiStefano DJ, Callahan C, Donnell GO, Galli JD, Swoyer R, Touch S, Wen Z, Antonello J, Zhang L, Flynn JA, Cox KS, Freed DC, Vora KA, Bahl K, Latham AH, Smith JS, Gindy ME, Ciaramella G, Hazuda D, Shaw CA, Bett AJ. Espeseth AS, et al. Among authors: bahl k. NPJ Vaccines. 2020 Feb 14;5(1):16. doi: 10.1038/s41541-020-0163-z. eCollection 2020. NPJ Vaccines. 2020. PMID: 32128257 Free PMC article.
Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells.
Lindgren G, Ols S, Liang F, Thompson EA, Lin A, Hellgren F, Bahl K, John S, Yuzhakov O, Hassett KJ, Brito LA, Salter H, Ciaramella G, Loré K. Lindgren G, et al. Among authors: bahl k. Front Immunol. 2017 Nov 13;8:1539. doi: 10.3389/fimmu.2017.01539. eCollection 2017. Front Immunol. 2017. PMID: 29181005 Free PMC article.
A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice.
Roth C, Cantaert T, Colas C, Prot M, Casadémont I, Levillayer L, Thalmensi J, Langlade-Demoyen P, Gerke C, Bahl K, Ciaramella G, Simon-Loriere E, Sakuntabhai A. Roth C, et al. Among authors: bahl k. Front Immunol. 2019 Jun 21;10:1424. doi: 10.3389/fimmu.2019.01424. eCollection 2019. Front Immunol. 2019. PMID: 31293584 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33580035
Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates.
Flynn JA, Weber T, Cejas PJ, Cox KS, Touch S, Austin LA, Ou Y, Citron MP, Luo B, Gindy ME, Bahl K, Ciaramella G, Espeseth AS, Zhang L. Flynn JA, et al. Among authors: bahl k. Vaccine. 2022 Jul 30;40(32):4412-4423. doi: 10.1016/j.vaccine.2022.03.063. Epub 2022 Jun 6. Vaccine. 2022. PMID: 35680500
Corrigendum: Induction of Robust B Cell Responses After Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells.
Lindgren G, Ols S, Liang F, Thompson EA, Lin A, Hellgren F, Bahl K, John S, Yuzhakov O, Hassett KJ, Brito LA, Salter H, Ciaramella G, Loré K. Lindgren G, et al. Among authors: bahl k. Front Immunol. 2019 Apr 2;10:614. doi: 10.3389/fimmu.2019.00614. eCollection 2019. Front Immunol. 2019. PMID: 31001251 Free PMC article.
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness.
Corbett KS, Edwards D, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, Dinnon KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Bahl K, Garcia-Dominguez D, Ma L, Renzi I, Kong WP, Schmidt SD, Wang L, Zhang Y, Stevens LJ, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanan E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, Nason MC, Ruckwardt TJ, McLellan JS, Denison MR, Chappell JD, Moore IN, Morabito KM, Mascola JR, Baric RS, Carfi A, Graham BS. Corbett KS, et al. Among authors: bahl k. bioRxiv [Preprint]. 2020 Jun 11:2020.06.11.145920. doi: 10.1101/2020.06.11.145920. bioRxiv. 2020. PMID: 32577634 Free PMC article. Updated. Preprint.
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.
Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schäfer A, Ziwawo CT, DiPiazza AT, Dinnon KH, Elbashir SM, Shaw CA, Woods A, Fritch EJ, Martinez DR, Bock KW, Minai M, Nagata BM, Hutchinson GB, Wu K, Henry C, Bahl K, Garcia-Dominguez D, Ma L, Renzi I, Kong WP, Schmidt SD, Wang L, Zhang Y, Phung E, Chang LA, Loomis RJ, Altaras NE, Narayanan E, Metkar M, Presnyak V, Liu C, Louder MK, Shi W, Leung K, Yang ES, West A, Gully KL, Stevens LJ, Wang N, Wrapp D, Doria-Rose NA, Stewart-Jones G, Bennett H, Alvarado GS, Nason MC, Ruckwardt TJ, McLellan JS, Denison MR, Chappell JD, Moore IN, Morabito KM, Mascola JR, Baric RS, Carfi A, Graham BS. Corbett KS, et al. Among authors: bahl k. Nature. 2020 Oct;586(7830):567-571. doi: 10.1038/s41586-020-2622-0. Epub 2020 Aug 5. Nature. 2020. PMID: 32756549 Free PMC article.
52 results